White paper: Developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs

Helen W. Boucher, Paul G. Ambrose, H. F. Chambers, Richard H. Ebright, Amanda Jezek, Barbara E. Murray, Jason G. Newland, Belinda Ostrowsky, John H. Rex

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Despite progress in antimicrobial drug development, a critical need persists for new, feasible pathways to develop antibacterial agents to treat people infected with drug-resistant bacteria. Infections due to resistant gram-negative bacilli continue to cause unacceptable morbidity and mortality rates. Antibacterial agents have been historically studied in noninferiority clinical trials that focus on a single site of infection (eg, complicated urinary tract infections, intra-abdominal infections), yet these designs may not be optimal, and often are not feasible, for study of infections caused by drug-resistant bacteria. Over the past several years, multiple stakeholders have worked to develop consensus regarding paths forward with a goal of facilitating timely conduct of antimicrobial development. Here we advocate for a novel and pragmatic approach and, toward this end, present feasible trial designs for antibacterial agents that could enable conduct of narrow-spectrum, organism-specific clinical trials and ultimately approval of critically needed new antibacterial agents.

Original languageEnglish (US)
Pages (from-to)228-236
Number of pages9
JournalJournal of Infectious Diseases
Volume216
Issue number2
DOIs
StatePublished - Jul 15 2017

Fingerprint

Anti-Bacterial Agents
Pharmaceutical Preparations
Infection
Clinical Trials
Intraabdominal Infections
Bacteria
Urinary Tract Infections
Bacillus
Morbidity
Mortality

Keywords

  • Antibiotic development
  • Antimicrobial resistance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Boucher, H. W., Ambrose, P. G., Chambers, H. F., Ebright, R. H., Jezek, A., Murray, B. E., ... Rex, J. H. (2017). White paper: Developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs. Journal of Infectious Diseases, 216(2), 228-236. https://doi.org/10.1093/infdis/jix211

White paper : Developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs. / Boucher, Helen W.; Ambrose, Paul G.; Chambers, H. F.; Ebright, Richard H.; Jezek, Amanda; Murray, Barbara E.; Newland, Jason G.; Ostrowsky, Belinda; Rex, John H.

In: Journal of Infectious Diseases, Vol. 216, No. 2, 15.07.2017, p. 228-236.

Research output: Contribution to journalArticle

Boucher, HW, Ambrose, PG, Chambers, HF, Ebright, RH, Jezek, A, Murray, BE, Newland, JG, Ostrowsky, B & Rex, JH 2017, 'White paper: Developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs', Journal of Infectious Diseases, vol. 216, no. 2, pp. 228-236. https://doi.org/10.1093/infdis/jix211
Boucher, Helen W. ; Ambrose, Paul G. ; Chambers, H. F. ; Ebright, Richard H. ; Jezek, Amanda ; Murray, Barbara E. ; Newland, Jason G. ; Ostrowsky, Belinda ; Rex, John H. / White paper : Developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs. In: Journal of Infectious Diseases. 2017 ; Vol. 216, No. 2. pp. 228-236.
@article{34c1709c92da41e0bc1bddc1418392ed,
title = "White paper: Developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs",
abstract = "Despite progress in antimicrobial drug development, a critical need persists for new, feasible pathways to develop antibacterial agents to treat people infected with drug-resistant bacteria. Infections due to resistant gram-negative bacilli continue to cause unacceptable morbidity and mortality rates. Antibacterial agents have been historically studied in noninferiority clinical trials that focus on a single site of infection (eg, complicated urinary tract infections, intra-abdominal infections), yet these designs may not be optimal, and often are not feasible, for study of infections caused by drug-resistant bacteria. Over the past several years, multiple stakeholders have worked to develop consensus regarding paths forward with a goal of facilitating timely conduct of antimicrobial development. Here we advocate for a novel and pragmatic approach and, toward this end, present feasible trial designs for antibacterial agents that could enable conduct of narrow-spectrum, organism-specific clinical trials and ultimately approval of critically needed new antibacterial agents.",
keywords = "Antibiotic development, Antimicrobial resistance",
author = "Boucher, {Helen W.} and Ambrose, {Paul G.} and Chambers, {H. F.} and Ebright, {Richard H.} and Amanda Jezek and Murray, {Barbara E.} and Newland, {Jason G.} and Belinda Ostrowsky and Rex, {John H.}",
year = "2017",
month = "7",
day = "15",
doi = "10.1093/infdis/jix211",
language = "English (US)",
volume = "216",
pages = "228--236",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - White paper

T2 - Developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs

AU - Boucher, Helen W.

AU - Ambrose, Paul G.

AU - Chambers, H. F.

AU - Ebright, Richard H.

AU - Jezek, Amanda

AU - Murray, Barbara E.

AU - Newland, Jason G.

AU - Ostrowsky, Belinda

AU - Rex, John H.

PY - 2017/7/15

Y1 - 2017/7/15

N2 - Despite progress in antimicrobial drug development, a critical need persists for new, feasible pathways to develop antibacterial agents to treat people infected with drug-resistant bacteria. Infections due to resistant gram-negative bacilli continue to cause unacceptable morbidity and mortality rates. Antibacterial agents have been historically studied in noninferiority clinical trials that focus on a single site of infection (eg, complicated urinary tract infections, intra-abdominal infections), yet these designs may not be optimal, and often are not feasible, for study of infections caused by drug-resistant bacteria. Over the past several years, multiple stakeholders have worked to develop consensus regarding paths forward with a goal of facilitating timely conduct of antimicrobial development. Here we advocate for a novel and pragmatic approach and, toward this end, present feasible trial designs for antibacterial agents that could enable conduct of narrow-spectrum, organism-specific clinical trials and ultimately approval of critically needed new antibacterial agents.

AB - Despite progress in antimicrobial drug development, a critical need persists for new, feasible pathways to develop antibacterial agents to treat people infected with drug-resistant bacteria. Infections due to resistant gram-negative bacilli continue to cause unacceptable morbidity and mortality rates. Antibacterial agents have been historically studied in noninferiority clinical trials that focus on a single site of infection (eg, complicated urinary tract infections, intra-abdominal infections), yet these designs may not be optimal, and often are not feasible, for study of infections caused by drug-resistant bacteria. Over the past several years, multiple stakeholders have worked to develop consensus regarding paths forward with a goal of facilitating timely conduct of antimicrobial development. Here we advocate for a novel and pragmatic approach and, toward this end, present feasible trial designs for antibacterial agents that could enable conduct of narrow-spectrum, organism-specific clinical trials and ultimately approval of critically needed new antibacterial agents.

KW - Antibiotic development

KW - Antimicrobial resistance

UR - http://www.scopus.com/inward/record.url?scp=85027869554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027869554&partnerID=8YFLogxK

U2 - 10.1093/infdis/jix211

DO - 10.1093/infdis/jix211

M3 - Article

C2 - 28475768

AN - SCOPUS:85027869554

VL - 216

SP - 228

EP - 236

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -